An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients

Andrew H. Limper, Kenneth S. Knox, George A. Sarosi, Neil M. Ampel, John E. Bennett, Antonino Catanzaro, Scott F. Davies, William E. Dismukes, Chadi A. Hage, Kieren Marr, Christopher H. Mody, John R. Perfect, David A. Stevens

Research output: Contribution to journalArticle

Abstract

With increasing numbers of immune-compromised patients with malignancy, hematologic disease, and HIV, as well as those receiving immunosupressive drug regimens for the management of organ transplantation or autoimmune inflammatory conditions, the incidence of fungal infections has dramatically increased over recent years. Definitive diagnosis of pulmonary fungal infections has also been substantially assisted by the development of newer diagnostic methods and techniques, including the use of antigen detection, polymerase chain reaction, serologies, computed tomography and positron emission tomography scans, bronchoscopy, mediastinoscopy, and video-assisted thorascopic biopsy. At the same time, the introduction of new treatment modalities has significantly broadened options available to physicians who treat these conditions. While traditionally antifungal therapy was limited to the use of amphotericin B, flucytosine, and a handful of clinically available azole agents, current pharmacologic treatment options include potent new azole compounds with extended antifungal activity, lipid forms of amphotericin B, and newer antifungal drugs, including the echinocandins. In view of the changing treatment of pulmonary fungal infections, the American Thoracic Society convened a working group of experts in fungal infections to develop a concise clinical statement of current therapeutic options for those fungal infections of particular relevance to pulmonary and critical care practice. This document focuses on three primary areas of concern: the endemic mycoses, including histoplasmosis, sporotrichosis, blastomycosis, and coccidioidomycosis; fungal infections of special concern for immune-compromised and critically ill patients, including cryptococcosis, aspergillosis, candidiasis, and Pneumocystis pneumonia; and rare and emerging fungal infections.

Original languageEnglish (US)
Pages (from-to)96-128
Number of pages33
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume183
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Mycoses
Critical Care
Lung
Fungal Lung Diseases
Azoles
Amphotericin B
Therapeutics
Sporotrichosis
Blastomycosis
Echinocandins
Coccidioidomycosis
Mediastinoscopy
Flucytosine
Cryptococcosis
Histoplasmosis
Pneumocystis Pneumonia
Aspergillosis
Hematologic Diseases
Candidiasis
Bronchoscopy

Keywords

  • Amphotericin
  • Echinocandin
  • Fungal pneumonia
  • Triazole antifungal

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

An official American Thoracic Society statement : Treatment of fungal infections in adult pulmonary and critical care patients. / Limper, Andrew H.; Knox, Kenneth S.; Sarosi, George A.; Ampel, Neil M.; Bennett, John E.; Catanzaro, Antonino; Davies, Scott F.; Dismukes, William E.; Hage, Chadi A.; Marr, Kieren; Mody, Christopher H.; Perfect, John R.; Stevens, David A.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 183, No. 1, 01.01.2011, p. 96-128.

Research output: Contribution to journalArticle

Limper, AH, Knox, KS, Sarosi, GA, Ampel, NM, Bennett, JE, Catanzaro, A, Davies, SF, Dismukes, WE, Hage, CA, Marr, K, Mody, CH, Perfect, JR & Stevens, DA 2011, 'An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients', American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 1, pp. 96-128. https://doi.org/10.1164/rccm.2008-740ST
Limper, Andrew H. ; Knox, Kenneth S. ; Sarosi, George A. ; Ampel, Neil M. ; Bennett, John E. ; Catanzaro, Antonino ; Davies, Scott F. ; Dismukes, William E. ; Hage, Chadi A. ; Marr, Kieren ; Mody, Christopher H. ; Perfect, John R. ; Stevens, David A. / An official American Thoracic Society statement : Treatment of fungal infections in adult pulmonary and critical care patients. In: American Journal of Respiratory and Critical Care Medicine. 2011 ; Vol. 183, No. 1. pp. 96-128.
@article{8b8cff7ef4b64a64b9131741269b8599,
title = "An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients",
abstract = "With increasing numbers of immune-compromised patients with malignancy, hematologic disease, and HIV, as well as those receiving immunosupressive drug regimens for the management of organ transplantation or autoimmune inflammatory conditions, the incidence of fungal infections has dramatically increased over recent years. Definitive diagnosis of pulmonary fungal infections has also been substantially assisted by the development of newer diagnostic methods and techniques, including the use of antigen detection, polymerase chain reaction, serologies, computed tomography and positron emission tomography scans, bronchoscopy, mediastinoscopy, and video-assisted thorascopic biopsy. At the same time, the introduction of new treatment modalities has significantly broadened options available to physicians who treat these conditions. While traditionally antifungal therapy was limited to the use of amphotericin B, flucytosine, and a handful of clinically available azole agents, current pharmacologic treatment options include potent new azole compounds with extended antifungal activity, lipid forms of amphotericin B, and newer antifungal drugs, including the echinocandins. In view of the changing treatment of pulmonary fungal infections, the American Thoracic Society convened a working group of experts in fungal infections to develop a concise clinical statement of current therapeutic options for those fungal infections of particular relevance to pulmonary and critical care practice. This document focuses on three primary areas of concern: the endemic mycoses, including histoplasmosis, sporotrichosis, blastomycosis, and coccidioidomycosis; fungal infections of special concern for immune-compromised and critically ill patients, including cryptococcosis, aspergillosis, candidiasis, and Pneumocystis pneumonia; and rare and emerging fungal infections.",
keywords = "Amphotericin, Echinocandin, Fungal pneumonia, Triazole antifungal",
author = "Limper, {Andrew H.} and Knox, {Kenneth S.} and Sarosi, {George A.} and Ampel, {Neil M.} and Bennett, {John E.} and Antonino Catanzaro and Davies, {Scott F.} and Dismukes, {William E.} and Hage, {Chadi A.} and Kieren Marr and Mody, {Christopher H.} and Perfect, {John R.} and Stevens, {David A.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1164/rccm.2008-740ST",
language = "English (US)",
volume = "183",
pages = "96--128",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - An official American Thoracic Society statement

T2 - Treatment of fungal infections in adult pulmonary and critical care patients

AU - Limper, Andrew H.

AU - Knox, Kenneth S.

AU - Sarosi, George A.

AU - Ampel, Neil M.

AU - Bennett, John E.

AU - Catanzaro, Antonino

AU - Davies, Scott F.

AU - Dismukes, William E.

AU - Hage, Chadi A.

AU - Marr, Kieren

AU - Mody, Christopher H.

AU - Perfect, John R.

AU - Stevens, David A.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - With increasing numbers of immune-compromised patients with malignancy, hematologic disease, and HIV, as well as those receiving immunosupressive drug regimens for the management of organ transplantation or autoimmune inflammatory conditions, the incidence of fungal infections has dramatically increased over recent years. Definitive diagnosis of pulmonary fungal infections has also been substantially assisted by the development of newer diagnostic methods and techniques, including the use of antigen detection, polymerase chain reaction, serologies, computed tomography and positron emission tomography scans, bronchoscopy, mediastinoscopy, and video-assisted thorascopic biopsy. At the same time, the introduction of new treatment modalities has significantly broadened options available to physicians who treat these conditions. While traditionally antifungal therapy was limited to the use of amphotericin B, flucytosine, and a handful of clinically available azole agents, current pharmacologic treatment options include potent new azole compounds with extended antifungal activity, lipid forms of amphotericin B, and newer antifungal drugs, including the echinocandins. In view of the changing treatment of pulmonary fungal infections, the American Thoracic Society convened a working group of experts in fungal infections to develop a concise clinical statement of current therapeutic options for those fungal infections of particular relevance to pulmonary and critical care practice. This document focuses on three primary areas of concern: the endemic mycoses, including histoplasmosis, sporotrichosis, blastomycosis, and coccidioidomycosis; fungal infections of special concern for immune-compromised and critically ill patients, including cryptococcosis, aspergillosis, candidiasis, and Pneumocystis pneumonia; and rare and emerging fungal infections.

AB - With increasing numbers of immune-compromised patients with malignancy, hematologic disease, and HIV, as well as those receiving immunosupressive drug regimens for the management of organ transplantation or autoimmune inflammatory conditions, the incidence of fungal infections has dramatically increased over recent years. Definitive diagnosis of pulmonary fungal infections has also been substantially assisted by the development of newer diagnostic methods and techniques, including the use of antigen detection, polymerase chain reaction, serologies, computed tomography and positron emission tomography scans, bronchoscopy, mediastinoscopy, and video-assisted thorascopic biopsy. At the same time, the introduction of new treatment modalities has significantly broadened options available to physicians who treat these conditions. While traditionally antifungal therapy was limited to the use of amphotericin B, flucytosine, and a handful of clinically available azole agents, current pharmacologic treatment options include potent new azole compounds with extended antifungal activity, lipid forms of amphotericin B, and newer antifungal drugs, including the echinocandins. In view of the changing treatment of pulmonary fungal infections, the American Thoracic Society convened a working group of experts in fungal infections to develop a concise clinical statement of current therapeutic options for those fungal infections of particular relevance to pulmonary and critical care practice. This document focuses on three primary areas of concern: the endemic mycoses, including histoplasmosis, sporotrichosis, blastomycosis, and coccidioidomycosis; fungal infections of special concern for immune-compromised and critically ill patients, including cryptococcosis, aspergillosis, candidiasis, and Pneumocystis pneumonia; and rare and emerging fungal infections.

KW - Amphotericin

KW - Echinocandin

KW - Fungal pneumonia

KW - Triazole antifungal

UR - http://www.scopus.com/inward/record.url?scp=78650794568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650794568&partnerID=8YFLogxK

U2 - 10.1164/rccm.2008-740ST

DO - 10.1164/rccm.2008-740ST

M3 - Article

C2 - 21193785

AN - SCOPUS:78650794568

VL - 183

SP - 96

EP - 128

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -